Multicentric phase II trial of TI‐CE high‐dose chemotherapy with therapeutic drug monitoring of carboplatin in patients with relapsed advanced germ cell tumors

Multicentric phase II trial of TI‐CE high‐dose chemotherapy with therapeutic drug monitoring of carboplatin in patients with relapsed advanced germ cell tumors

ABSTRACT Background High‐dose chemotherapy (HDCT) with TI‐CE regimen is a valid option for the treatment of relapsed advanced germ cell tumors (GCT). We report a phase II trial with therapeutic drug monitoring of carboplatin for optimizing area under the curve (AUC) of this drug. Methods Patients wi...

Full description

Bibliographic Details
Main Authors: Christine Chevreau, Christophe Massard, Aude Flechon, Rémy Delva, Gwenaëlle Gravis, Jean‐Pierre Lotz, Jacques‐Olivier Bay, Marine Gross‐Goupil, Karim Fizazi, Loïc Mourey, Angelo Paci, Jérôme Guitton, Fabienne Thomas, Bénédicte Lelièvre, Joseph Ciccolini, Sotheara Moeung, Yohan Gallois, Pascale Olivier, Stéphane Culine, Thomas Filleron, Etienne Chatelut
Format: Article
Language:English
Published: Wiley 2021-04-01
Series:Cancer Medicine
Subjects:
germ cell tumors
high‐dose chemotherapy
phase II trial
relapsed patients
therapeutic drug monitoring
Online Access:https://doi.org/10.1002/cam4.3687

Internet

https://doi.org/10.1002/cam4.3687

Similar Items